Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation
Sponsor: ECOG-ACRIN Cancer Research Group
A PHASE3 clinical study on Adenocarcinoma of the Rectum and Stage II Rectal Cancer, this trial is terminated or withdrawn. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Aug 2023 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Dec 2020 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .